Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 10/20 | 0.55 |
| ▸ | HTR1A | P08908 | 5/20 | 0.55 |
| ▸ | DRD3 | P35462 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18350077 | 0.85 | DRD2 (0.59) | DRD2HTR1ADRD3 | |
| SCHEMBL13487690 | 0.82 | DRD2 (0.66) | DRD2HTR1ADRD3 | |
| SCHEMBL29640488 | 0.78 | DRD2 (0.52) | DRD2HTR1ADRD3 | |
| SCHEMBL7728944 | 0.78 | DRD2 (0.52) | DRD2HTR1ADRD3 | |
| SCHEMBL10454756 | 0.78 | DRD2 (0.52) | DRD2HTR1ADRD3 | |
| SCHEMBL10454755 | 0.78 | DRD2 (0.52) | DRD2HTR1ADRD3 | |
| SCHEMBL11514315 | 0.78 | DRD2 (0.52) | DRD2HTR1ADRD3 | |
| SCHEMBL11514328 | 0.78 | DRD2 (0.52) | DRD2HTR1ADRD3 | |
| SCHEMBL11823284 | 0.77 | DRD2 (0.55) | DRD2DRD3 | |
| SCHEMBL30864984 | 0.76 | ACHE (0.46) | DRD2HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024059951-A1 | INHIBITORS OF THE ANDROGEN RECEPTOR DNA-BINDING DOMAIN | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2024-03-28 | — | — | WO | disclosed |
| US-20160219879-A1 | FUNGICIDAL COMPOSITIONS | SYNGENTA PARTICIPATIONS AG (CH) | 2016-08-04 | — | — | US | disclosed |
| US-9326513-B2 | Fungicidal compositions | SYNGENTA PARTICIPATIONS AG (CH) | 2016-05-03 | — | — | US | disclosed |
| US-20140335201-A1 | FUNGICIDAL COMPOSITIONS | SYNGENTA PARTICIPATIONS AG (CH) | 2014-11-13 | — | — | US | disclosed |
| EP-0966436-A1 | ARYL SULFONAMIDES AND ANALOGUES THEREOF AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | Bayer Aktiengesellschaft (DE) | 1999-12-29 | — | — | EP | disclosed |
| WO-1998037061-A1 | ARYL SULFONAMIDES AND ANALOGUES THEREOF AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | BAYER AKTIENGESELLSCHAFT (DE) | 1998-08-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140335201-A1 | FUNGICIDAL COMPOSITIONS | CYP1B1, CYP4B1, DDT | DRD2 2150/4885HTR1A 3652/4885DRD3 2305/4885 |
| US-20160219879-A1 | FUNGICIDAL COMPOSITIONS | CYP1B1, CYP4B1, DDT | DRD2 2150/4885HTR1A 3652/4885DRD3 2305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.